Key Trial Results for Lurbinectedin
Lurbinectedin (branded as Zepzelca) met its primary endpoint in the phase 3 ATLANTIS trial for relapsed small cell lung cancer (SCLC). The study compared lurbinectedin plus irinotecan against topotecan in 421 patients, showing a median overall survival of 10.3 months versus 9.3 months (HR 0.92, p=0.37), which did not reach statistical significance for superiority. Progression-free survival improved to 5.1 months from 3.7 months (HR 0.68, p<0.0001).[1][2]
In the phase 2basket trial (NCT02454972), lurbinectedin monotherapy produced an overall response rate of 35% in SCLC, with median duration of response at 5.3 months and overall survival at 11.8 months in sensitive relapse cases.[3]
FDA Approval and Real-World Use
The FDA granted accelerated approval in June 2020 for metastatic SCLC after platinum-based therapy, based on the phase 2 trial's 35% response rate and 11.1-month median survival. Full approval requires confirmatory data; ATLANTIS did not convert it to full status.[1][4]
Post-approval, it's used second-line after progression on platinum chemo, with ongoing trials exploring combinations.
Performance in Other Cancers
Early promise emerged in trials for:
- Mesothelioma: Phase 2 showed 21% response rate, median survival 13.3 months.[5]
- BRCA1/2-mutant cancers: 45% response rate in a phase 2 study.[6]
- Urothelial carcinoma: 25% response rate in platinum-refractory cases.[7]
These led to orphan drug designations but no additional approvals yet.
Comparison to Standard Treatments
In SCLC, lurbinectedin outperformed topotecan in response rate (35% vs 13%) and PFS in the phase 2 trial, with better tolerability (less grade 3/4 cytopenias). ATLANTIS confirmed PFS benefit but not OS superiority over topotecan/irinotecan.[2][3] It offers a chemotherapy alternative with distinct transcription inhibition mechanism.
Ongoing Trials and Future Outlook
Over 20 trials are active, including phase 3 IMforte (SCLC maintenance with atezolizumab) and combinations with doxorubicin for soft tissue sarcoma. Pediatric studies for Ewing sarcoma are recruiting.[8] Patent protection extends to 2033 in the US.[9]
No major safety signals beyond myelosuppression; common issues include neutropenia (57%) and fatigue (32%).[1]
Sources
[1]: FDA Approval Summary
[2]: ATLANTIS Trial (JAMA Oncol 2024)
[3]: Phase 2 Basket Trial (Lancet Oncol 2019)
[4]: Zepzelca Prescribing Info
[5]: Mesothelioma Phase 2 (Lung Cancer 2021)
[6]: BRCA Trial (Clin Cancer Res 2020)
[7]: Urothelial Phase 2 (ESMO 2020)
[8]: ClinicalTrials.gov Search for Lurbinectedin
[9]: DrugPatentWatch.com - Lurbinectedin Patents